Another Attempt To Expand Nexavar Label Ends In Disappointment
This article was originally published in The Pink Sheet Daily
Bayer/Amgen’s Nexavar fails to improve progression-free survival in a Phase III HER2-negative breast cancer study. Approved indications are not affected, the companies note.
You may also be interested in...
Failed MISSION trial closes a door for Bayer/Onyx’s Nexavar in non-small cell lung cancer. Meanwhile, follow-on regorafenib, also partnered by Bayer and Onyx, is poised for submission in the U.S. and Europe for metastatic colon cancer, with ASCO presentations ahead.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.